Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  

Journal of Clinical Toxicology

Open Access
ISSN: 2161-0495
home » monocarboxylate-transporter-inhibition-with-osmotic-diuresis-hydroxybutyrate-renal-elimination-2161-0495 Rss Feed Rss Feed
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and
Workshops on Pharma, Medicine, Science and Technology
Research Article Open Access
Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study
1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY (Morris and Morse) Marilyn E. Morris1*, 1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY (Morris and Morse) Bridget L. Morse1, 2Department of Psychiatry, University of Rochester Medical Center, University of Rochester, Rochester, NY (Baciewicz and Tessena) Gloria J. Baciewicz2, 2Department of Psychiatry, University of Rochester Medical Center, University of Rochester, Rochester, NY (Baciewicz and Tessena) Matthew M. Tessena2, 3Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, University of Rochester, Rochester, NY (Acquisto) Nicole M. Acquisto3, 4Department of Pharmacy Practice, School of Pharmacy, St. John Fisher College, Rochester, NY (Hutchinson) David J. Hutchinson4
and 5Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY (DiCenzo) Robert DiCenzo5
Corresponding Author : Marilyn E. Morris
University at Buffalo, 527 Hochstetter Hall Buffalo, NY 14260
Tel: (716) 645-4839
Fax: (716) 645-3693
E-mail: memorris@buffalo.edu
Received October 01, 2011; Accepted November 03, 2011; Published November 10, 2011
Citation: Morris ME, Morse BL, Baciewicz GJ, Tessena MM, Acquisto NM, et al. (2011) Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases ?-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study. J Clinic Toxicol 1:105. doi: 10.4172/2161- 0495.1000105
Copyright: © 2011 Morris ME, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Visit for more related articles at
DownloadJournal of Clinical Toxicology

Background and objective: The purpose of the current study was to demonstrate proof-of-concept that monocarboxylate transporter (MCT) inhibition with L-lactate combined with osmotic diuresis increases renal clearance of ?-hydroxybutyrate (GHB) in human subjects. GHB is a substrate for human and rodent MCTs, which are responsible for GHB renal reabsorption, and this therapy increases GHB renal clearance in rats Methods: Ten healthy volunteers were administered GHB orally as sodium oxybate 50 mg/kg (4.5 gm maximum dose) on two different study days. On study day 1, GHB was administered alone. On study day 2, treatment of L-lactate 0.125 mmol/kg and mannitol 200 mg/kg followed by L-lactate 0.75 mmol/kg/hr was administered intravenously 30 minutes after GHB ingestion. Blood and urine were collected for 6 hours, analyzed for GHB, and pharmacokinetic and statistical analyses performed. Results: L-lactate/mannitol administration significantly increased GHB renal clearance compared to GHB alone, 439 vs. 615 mL/hr (P=0.001), and increased the percentage of GHB dose excreted in the urine, 2.2 vs. 3.3% (P=0.021). Total clearance was unchanged. Conclusions: MCT inhibition with L-lactate combined with osmotic diuresis increases GHB renal elimination in humans. No effect on total clearance was observed in this study due to the negligible contribution of renal clearance to total clearance at this low GHB dose. Considering the nonlinear renal elimination of GHB, further research in overdose cases is warranted to assess the efficacy of this treatment strategy for increasing renal and total clearance at high GHB doses.

γ-hydroxybutyrate; Pharmacokinetics; Renal clearance; Monocarboxylate transporter
AUC: Area under the plasma concentration-time curve; Cl: Clearance; ClR: Renal clearance; CV: Coefficient of variation; F: Bioavailability; GHB: γ-hydroxybutyrate; MCT: Monocarboxylate transporter
Overdose of ã-hydroxybutyrate (GHB) and its precursors, ã-butyrolactone and 1,4-butanediol, has recently been recognized as a significant issue in public health. From 1990-2000, over 7100 GHB overdoses including 65 deaths were reported in the U.S. [1], and in a recent publication, 209 GHB-associated deaths were reported in the U.S. from 1995-2005 [2]. Manifestations of GHB overdose include sedation, coma, hypothermia, bradycardia, and respiratory arrest [3-5]. Although abuse of GHB has been recognized, there currently exists no pharmacological treatment for the overdose of these compounds. Current treatment consists primarily of supportive care and mechanical ventilation in cases of significant respiratory depression [6,7].
GHB is currently used in the form of sodium oxybate (Xyrem®) for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy in the U.S. and in Europe. Clinical studies with sodium oxybate demonstrate dose-dependent pharmacokinetics, even at low, therapeutic doses [8,9]. Similar pharmacokinetic properties are reported in rats, in which nonlinearity has been attributed to several concentration-dependent processes including saturable metabolism, oral absorption, and renal reabsorption [10-12]. Saturable renal reabsorption in rats can be accounted for by saturable transport by monocarboxylate transporters (MCTs), of which GHB is a substrate [10,13]. In the kidney, MCTs act to conserve endogenous monocarboxylates, such as lactate, from being cleared into the urine, and serve a similar role in the conservation of GHB. Increasing GHB renal elimination by inhibition of these transporters represents a potential therapeutic strategy for the treatment of GHB overdose. This strategy has been validated using rat kidney membrane vesicles and in vivo rat studies to demonstrate that administration of MCT inhibitors inhibits GHB transport in the kidney and effectively increases GHB total and renal clearance at high GHB doses [10,13-15]. Using a human kidney cell line, MCT inhibitors similarly inhibited the transport of GHB in human tissue [16].
Although well-established in rodents, the role of MCTs in the renal elimination of GHB in humans has not been demonstrated in vivo. The purpose of this study was to provide proof-of-concept that administration of an MCT inhibitor, L-lactate, combined with osmotic diuresis increases the renal clearance of GHB in human subjects.
Materials and Methods
Study design and selection of participants
This was a prospective, open-label, crossover study performed at a university hospital from 2009-2011. This study was approved by the institutional review boards at the sponsoring institutions. Healthy male and female volunteers, ages 21-55, were recruited for the study. A screening visit was used to determine subjects in good health considering medical history, physical examination, and laboratory tests. Women of child-bearing age were administered a pregnancy test at the screening visit and were required to use an acceptable method of contraception throughout the study. Exclusion criteria included evidence of organ dysfunction as determined by physical examination and laboratory results, history of drug or alcohol abuse within 6 months prior to the study, allergy to study medications, known succinic semialdehyde dehydrogenase deficiency, women who were pregnant, breastfeeding or unwilling to use an acceptable method of contraception, and prescription or non-prescription drug use within 1 week prior to the study, excluding oral contraceptives or other medications approved by the investigator.
On study day 1, subjects were administered sodium oxybate 50 mg/ kg (4.5 gm maximum dose) orally in water. Subjects were instructed to fast overnight until they were served breakfast 2 hours after drug administration and to withhold caffeine ingestion on study days. On study day 2, subjects were administered sodium oxybate 50 mg/ kg (4.5 gm maximum dose) orally, and treatment was administered intravenously at 30 minutes after GHB ingestion. Treatment consisted of a 0.125 mmol/kg L-lactate bolus over 10 minutes and a 200 mg/kg bolus of mannitol over 3 – 5 minutes, followed by a 0.75 mmol/kg/ hr L-lactate infusion for the duration of the study. The L-lactate bolus and infusion were administered as sodium lactate 1/6 M solution for infusion. Mannitol was administered as a 20% solution in normal saline. In some subjects the study days were conducted in opposite order. Regardless of order, a washout period of at least 1 week was required between study days.
Data collection
Blood samples were taken on both study days directly before and at 10, 15, 20, 25, 30, 45, 60, 90, 120, 150, 180, 210, 240, and 360 minutes after GHB administration. A spot urine was collected predose and urine samples were collected at intervals of 0-30, 30-60, 60-120, 120- 180, 180-240, and 240-360 minutes after GHB administration. GHB plasma and urine concentrations were determined using an LC/MS/ MS assay [17,18]. Urine volume at urine collection intervals were recorded and multiplied by urine concentrations to determine the total amount of GHB recovered at each urine collection interval. On study day 2, plasma lactate concentrations were also taken at baseline and at 180 minutes after GHB administration. Plasma lactate concentrations were determined by a colorimetric lactate oxidase assay. Vital signs and adverse events were continuously monitored on both study days. On study day 2, an electrocardiogram was recorded via telemetry from time zero to 6 hours after study drug administration and a physical examination was performed prior to release.
Data and statistical analysis
Pharmacokinetic parameters were determined by noncompartmental analysis using WinNonlin 5.2 (Pharsight Corp., Palo Alto, CA). Primary outcome measurements included GHB renal clearance (ClR) and the percentage of GHB excreted unchanged in the urine. Other outcome measurements included total clearance (CL/F), area under the plasma-concentration time curve (AUC), and maximum plasma concentration (Cmax). Individual AUCs were determined by the trapezoidal method, where the measured plasma concentrations represented >95% the total AUC. Cl/F was determined as Dose/AUC. ClR was determined by Ae/AUC where Ae represents the amount of GHB recovered unchanged in the urine. Paired t-tests were used to determine statistically significant differences in mean pharmacokinetic parameters between study days. Statistical analyses were performed using SigmaPlot 10.0 (Systat Software, Inc., San Jose, CA). In this study, a 20% change in ClR was considered significant. Considering previous reports of 25% coefficient of variation (CV) values in GHB clearance [19] using α=0.05 and power of 0.8, 12 subjects were determined necessary to detect significant differences in measured pharmacokinetic parameters.
A total of 21 subjects voluntarily gave informed consent for the study. Of these, 15 subjects completed the screening visit and 10 subjects completed both study days and were included in the statistical analyses. Primary outcome measurements were met with this sample size; therefore recruitment was concluded. Demographics and baseline characteristics of the 10 subjects are given in Table 1. No significant differences in renal or liver function tests were detected between study days.
Pharmacokinetic parameters determined for both study days are given in Table 2. As shown, administration of L-lactate and mannitol significantly increased GHB renal clearance and the percentage of GHB dose excreted in the urine. Individual changes in renal clearance are displayed in Figure 1. GHB plasma AUC and total clearance were unchanged between study days. Administration of L-lactate on study day 2 increased the plasma lactate level from 0.9 ± 0.2 mM at baseline to 2.6 ± 0.8 mM at 180 minutes (mean ± SD, P<0.001). Adverse effects were similar between study days and were limited to light sedation, headache, dizziness, and nausea/vomiting. No effects on heart rate, blood pressure, or ECG were observed.
Although GHB abuse has resulted in an increasing incidence of overdose case reports and fatalities, treatment for these cases remains limited to supportive measures. Treatment with antidotes including flumazenil, naloxone, and physostigmine has been attempted, with little effect on clinical course [6]. Administration of GABAB antagonists has been demonstrated effective for treating overdose in rodent studies [20,21]; however, these agents are not currently available for use in humans. This study was performed to assess the ability of a clinically available treatment strategy of L-lactate and mannitol to increase GHB renal elimination. The treatment strategy including MCT inhibition and osmotic diuresis was chosen based upon results of previous animal studies [10,14,15]. L-lactate was chosen as the MCT inhibitor based upon its ability to increase renal and total clearances of GHB in rats along with its demonstrated safety in humans at the effective doses [15,22,23]. The addition of mannitol as an osmotic diuretic was based upon animal experiments demonstrating an increased effect with the combination of L-lactate and mannitol compared to L-lactate alone [15]; however, the contribution of mannitol to overall effects on GHB toxicokinetics remains uncertain. L-lactate effectively increased GHB renal and total clearance in animal studies in the absence of mannitol [10,15], as has also been demonstrated with other MCT inhibitors [14]. Ongoing animal studies are being conducted to determine the benefit of mannitol co-administration on the improvement of GHB toxicokinetic and toxicodynamic endpoints with MCT inhibitors.
Although the renal clearance of GHB was increased in this study, there was no effect of treatment on total clearance. At low, therapeutic GHB doses, such as that studied currently, the primary route of elimination is metabolism by GHB dehydrogenase to form succinic semialdehyde, which is then metabolized by succinic semialdehyde dehydrogenase to succinic acid, which enters the Krebs cycle at is excreted as carbon dioxide [9]. Renal excretion represents a minor route of elimination at low doses, as illustrated in this study with only approximately 2% of the total dose excreted into the urine. In both humans and rats, GHB metabolism is saturable [8,10,11], and contributes less to overall clearance as doses are increased [10]. In rats, nonlinear GHB renal clearance has also been well-characterized, and, in contrast with metabolism, the contribution of renal elimination to total clearance increases with dose [10]. In clinical studies, the urinary recovery of GHB has also been demonstrated to increase with dose [9], suggesting similar nonlinear renal elimination in humans. Accordingly, extremely high urine concentrations have been reported in overdose cases [24-26]. At low GHB doses, when renal elimination is negligible, even a significant increase in renal clearance with treatment administration would not be expected to significantly affect total clearance, as was observed in this study. However, in clinical GHB overdose, due to both concentration-dependent renal reabsorption and saturation of metabolism, renal clearance may contribute significantly to total drug elimination, allowing the increase in renal clearance demonstrated in this study to translate to increased total clearance, a concept which has been demonstrated in our animal studies of GHB overdose. In animal studies, the increase in clearance and decrease in GHB plasma concentrations with MCT inhibition also resulted in improvement in the toxicodynamic endpoint of sedation [14,15]. In the current study, the low dose and lack of effect on total clearance limited the pharmacodynamic evaluation possible with this study, as changes in total AUC would be necessary to expect differences in pharmacodynamic endpoints. Animal studies are in progress to further assess the effect of a clinically relevant dose of L-lactate with and without mannitol on toxicodynamic endpoints of GHB overdose including sedation, respiratory depression, and fatality.
Although this study demonstrated a statistically significant increase in renal clearance with L-lactate/mannitol administration, this increase in renal clearance of approximately 40% is modest compared to that observed in animal studies [10,15]. Since L-lactate is a competitive inhibitor of MCTs, increasing the L-lactate dose may have greater effects on GHB renal clearance. The dose of L-lactate administered in this clinical study is moderate, and higher infusion rates have been administered safely to human subjects [23]. Animal studies are being conducted to compare a similar L-lactate/mannitol regimen as that administered in this study with high-dose L-lactate/mannitol regimens.
The primary limitation of this study was the low GHB dose used, which reflects therapeutic dosing and not that in overdose cases. This excluded the evaluation of possible effects of treatment on total GHB clearance or pharmacodynamic endpoints. Due to the short half-life of GHB at the low dose used, treatment was administered 30 minutes after GHB administration in this study; in the clinic, treatment is not likely to be available this quickly after GHB ingestion. However, following overdoses, delayed peak plasma concentrations may occur, perhaps hours after ingestion as observed in animal studies [11], which may provide the opportunity for treatment at later time points. Finally, with the administration of L-lactate and mannitol concomitantly in this study, effects of MCT inhibition or osmotic diuresis alone on GHB renal clearance cannot be determined.
This pilot study demonstrates the proof-of-concept that MCT inhibition with L-lactate in combination with osmotic diuresis increases GHB renal elimination in humans. Administration of L-lactate and mannitol may represent a practical potential strategy for GHB overdose due to the clinical availability and low risk associated with these agents. Further research in GHB overdose cases is needed to determine the efficacy of this treatment strategy for increasing GHB total clearance and improving clinical course during GHB intoxication.
This research was supported by the National Institutes of Health National Institute on Drug Abuse [grant DA023223] to MEM and by a fellowship from Pfizer Global Research and Development to BLM.
Sodium oxybate (Xyrem®) was provided by Jazz Pharmaceuticals, Inc., Palo Alto, CA.
The authors would like to acknowledge Alyse DiCenzo for protocol conduct and data management during the study.



 Download    pdf version of this article


Tables at a glance

Table 1  Table 2

Figures at a glance

Figure 1
Select your language of interest to view the total content in your interested language
Share This Article
Relevant Topics
Disc Adverse Drug Reactions
Disc Anti-Cancer Drugs
Disc Anti-tumor Antibiotics
Disc Antimetabolites
Disc Antineoplastic Agents
Disc Anvisa Drug Safety Regulations
Disc Applied Toxicology
Disc Aquatic Toxicology
Disc Avastin
Disc Biochemical Metabolism
Disc Biomedical Toxicology
Disc Carcinogens
Disc Chemo Side Effects
Disc Chemotherapy
Disc Chemotherupatic Agents
Disc Clinical Pharmacoepidemiological Trails
Disc Clinical Toxicology
Disc Computational Toxicology
Disc Cutaneous Toxicology
Disc Cytochrome 450 Drug Metabolism
Disc Cytotoxic Drugs
Disc Cytotoxicity
Disc Detoxification
Disc Drug Delivery
Disc Drug Delivery Systems
Disc Drug Development
Disc Drug Discovery
Disc Drug Interaction
Disc Drug Interactions
Disc Drug Metabolism
Disc Drug Reactions
Disc Drug Safety Databases
Disc Drug Safety Information Maintenance
Disc Drug Safety Regulations
Disc Drug Therapy
Disc Drug drug interaction
Disc Drug food interaction
Disc Drugs metabolised by CYP2D6
Disc Environmental Chemical Toxicology
Disc Environmental Contamination Toxicology
Disc Environmental Mutagenicity
Disc Environmental Toxicology
Disc Europeon Drug Safety Regulations
Disc Excitotoxicity
Disc Experimental Toxicology
Disc Expert Opinions on Drug Safety
Disc Fluorouracil (5-FU)
Disc Genetic Toxicology
Disc Hepatic Metabolism of Drugs
Disc Hormonal Drugs for Cancer Therapy
Disc Inhalation Toxicology
Disc Insect Toxins
Disc Liver Drug Metabolism
Disc Medication Errors
Disc Methotrexate
Disc Microbial Toxins
Disc Mitotic Inhibitors
Disc Molecular Toxicology
Disc Mycotoxin
Disc Neuro Toxicology
Disc Occular Toxicology
Disc Occupational Toxicology
Disc Pediatric Toxicology
Disc Persistent Organic Pollutants
Disc Pharmaceutical Industry
Disc Pharmaceutical Toxicology
Disc Pharmacoepidemiological Studies
Disc Pharmacotherapy
Disc Pharmocology of Cancer Drugs
Disc Phase I Drug Metabolism
Disc Phase II Drug Metabolism
Disc Poisonous Effects
Disc Pollution management
Disc Pre-Clinical Drug Development
Disc Predictive Environmental Toxicology
Disc Purine Antagoinsts for Cancer Treatment
Disc Regulatory updates of Environmental Toxicology
Disc Reviews on Drug Safety
Disc Sewage Pollution
Disc Topoisomerase Inhibitors
Disc Toxicity
Disc Toxicology Methods and Mechanisms
Disc Toxin
Disc UK Drug Safety Regulations
Disc US Drug Safety Regulations
Disc Veterinary Toxicology
Disc Vinblastine
Related Journals
Disc Cancer Medicine & Anti Cancer Drugs Journal
Disc Developing Drugs Journal
Disc Drug Metabolism & Toxicology Journal
Disc Environmental and Analytical Toxicology Journal
Disc Pharmacoepidemiology and Drug Safety Journal
Related Conferences
Disc 2nd Conference on Therapeutic Drug Monitoring and Toxicogenomics
June 9-10, 2016 Dallas, USA
Disc International Conference on Environmental Toxicology and Ecological Risk Assessment
August 25-26, 2016 Sao Paulo, Brazil
Disc 5th Global Summit on Toxicology and Applied Pharmacology
Sept 19-21, 2016 Las Vegas, USA
Disc Euro-Global Summit on Toxicology and Applied Pharmacology
Oct 27-29, 2016 Rome, Italy
Article Tools
Disc Export citation
Disc Share/Blog this article

Post your comment

Your question:
Anti Spam Code:
  Reload  Can't read the image? click here to refresh

OMICS International Conferences 2015-16

Meet Inspiring Speakers and Experts at our 1000+ Global Annual Meetings
Conferences By Country
  USA   Spain   Poland
  Australia   Canada   Austria
  UAE   Switzerland   Turkey
  Italy   France   Finland
  Germany   India   Ukraine
  UK   Malaysia   Denmark
  Japan   Singapore   Mexico
  Brazil   South Africa   Norway
  South Korea   New Zealand   China
  Netherlands   Philippines
Medical & Clinical Conferences
Microbiology Oncology & Cancer
Diabetes & Endocrinology Cardiology
Nursing Dentistry
Healthcare Management Physical Therapy Rehabilitation
Neuroscience Psychiatry
Immunology Infectious Diseases
Gastroenterology Medical Ethics & Health Policies
Genetics & Molecular Biology Palliativecare
Pathology Reproductive Medicine & Women Healthcare
Alternative Healthcare Surgery
Pediatrics Radiology
Conferences by Subject
Pharmaceutical Sciences
Pharma Marketing & Industry
Environmental Science
Physics & Materials Science
EEE & Engineering
Chemical Engineering
Business Management
Geology & Earth science
©2008-2015 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version